|Bid||0.00 x 1100|
|Ask||0.00 x 2900|
|Day's Range||6.77 - 7.01|
|52 Week Range||6.77 - 24.48|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target
Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Bridgewater, New Jersey-based company said it had a loss of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 14 cents per share. The results missed Wall Street expectations. ...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.
Amneal Pharmaceuticals Inc (NYSE:AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
Genentech bought InterMune and the Brisbane company's idiopathic pulmonary fibrosis drug Esbriet for more than $8 billion in fall 2014. Now it faces pressure from more than a dozen generic drug makers.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) P/E ratio and reflect Read More...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]
A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.
Attractive stocks have exceptional fundamentals. In the case of Amneal Pharmaceuticals Inc (NYSE:AMRX), there’s is a company with a buoyant growth outlook, which has not yet been factored into the Read More...
On a per-share basis, the Bridgewater, New Jersey-based company said it had profit of 5 cents. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The results surpassed Wall Street ...
Two generic drugmakers can knock off Johnson & Johnson's blockbuster cancer treatment, Zytiga, as soon as Wednesday — but an analyst remained bullish Monday on the Dow Jones stock.
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about the link between company’s fundamentals and stock market performance. Read More...